Bluebird bio is to launch a $150m public offering of shares in a bid to finance its troubled gene therapy business, but even if this fundraising is successful, many analysts remain doubtful about the company’s long-term viability.
Key Takeaways
-
Bluebird Bio is looking to raise $150m to help finance its business into 2024
-
But the outlook for the company looks dire, despite the approval of its groundbreaking gene therapy Lyfgenia
That is because its problems go beyond a short-term cash flow issue: analysts predict limited traction for its products and judge its commercial strategy to be off